Status:
COMPLETED
Janus Kinase 1 in Vitiligo & Psoriasis
Lead Sponsor:
Cairo University
Conditions:
Vitiligo
Eligibility:
All Genders
12+ years
Phase:
NA
Brief Summary
Assessment of the level of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB which is considered a gold standard therapy for both diseases.
Eligibility Criteria
Inclusion
- age above 12 years of age.
- psoriasis vulgaris or non-segmental vitiligo
- patients who received no systemic or topical treatment at least 6 weeks prior to enrollment into the study.
Exclusion
- psoriasis patients with erythrodermic psoriasis, pustular psoriasis or associated psoriatic arthritis
- vitiligo patients with segmental or universal vitiligo were excluded from the study.
- any patient with a photosensitive disorder or any contraindication to phototherapy exposure, e.g., history or presence of malignant or premalignant skin lesions.
Key Trial Info
Start Date :
December 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2016
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03762551
Start Date
December 1 2015
End Date
November 1 2016
Last Update
December 3 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.